← Back to all trials
Active Not Recruiting
NCT02538198
Lenalidomide Maintenance in Plasma Cell Myeloma
Conditions: Plasma Cell Myeloma
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE2
Enrollment: 108
Sponsor: Memorial Sloan Kettering Cancer Center
Location: Memorial Sloan Kettering Cancer Center Basking Ridge New Jersey
Summary
This is a Phase 2 study to assess the good and bad effects of maintenance therapy on patients who have been treated for myeloma and no longer show signs of this type of cancer.
Eligibility Criteria
Inclusion Criteria:
* Patients with plasma cell myeloma treated with induction therapy or re-induction therapy, who at the time of study enrollment have documented evidence of stable disease response or better according to International Myeloma Workshop Consensus Panel
* Age ≥18 years. Because no dosing or adverse event data are currently available on the use of lenalidomide in patients \
Source: ClinicalTrials.gov (NCT02538198). StuddyBuddy aggregates publicly available trial information.
